amotosalen has been researched along with Neoplasms in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Garban, F; Heddle, NM; McCullough, J; Rebulla, P; van der Meer, PF | 1 |
Compernolle, V; Feys, HB; Van Aelst, B | 1 |
Ahmadi, M; Aspord, C; Broisat, A; Chauchet, X; Cretin, F; Genestet, C; Ghezzi, C; Laurin, D; Le Gouëllec, A; Martin, S; Plumas, J; Polack, B; Toussaint, B; Trocme, C; Verove, J; Wang, Y | 1 |
2 review(s) available for amotosalen and Neoplasms
Article | Year |
---|---|
A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets.
Topics: Blood Platelets; Disinfection; Furocoumarins; Hematologic Diseases; Humans; Neoplasms; Platelet Transfusion; Randomized Controlled Trials as Topic; Riboflavin; Ultraviolet Rays | 2020 |
Biomolecular Consequences of Platelet Pathogen Inactivation Methods.
Topics: Blood Banks; Blood Platelets; Blood Preservation; Blood Transfusion; Furocoumarins; Hemostasis; Humans; Neoplasms; Nucleic Acids; Platelet Transfusion; Riboflavin; Signal Transduction; Thrombocytopenia; Ultraviolet Rays | 2019 |
1 other study(ies) available for amotosalen and Neoplasms
Article | Year |
---|---|
A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.
Topics: Animals; Antigen Presentation; Antigens; Bacterial Secretion Systems; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Epitopes, T-Lymphocyte; Female; Furocoumarins; Humans; Immunity, Cellular; Immunotherapy; Lymphoid Tissue; Mice; Mutation; Neoplasms; Photosensitizing Agents; Pseudomonas aeruginosa; Vaccines, Attenuated; Xenograft Model Antitumor Assays | 2013 |